Prof Meletios Dimopoulos speaks to ecancer about cytogenetic risk analysis from the PERSEUS trial.

This trial investigated daratumumab (DARA)/bortezomib/lenalidomide/dexamethasone (D-VRd) with D-R maintenance in transplant-eligible (TE) newly diagnosed myeloma (NDMM) patients.

The study found that DARA plus VRd induction/consolidation and R maintenance improves progression-free survival and induces higher rates of deep and sustained responses compared to VRd induction/consolidation and R maintenance therapy across all cytogenetic risk subgroups.

These data support D-VRd induction/consolidation and D-R maintenance as a new standard of care for transplant-eligible NDMM, regardless of cytogenetic risk status.